Romvimza (vimseltinib) — United Healthcare

Initial criteria

• Diagnosis of tenosynovial giant cell tumor (TGCT)
• Surgical resection will potentially cause worsening functional limitation or severe morbidity
• OR
• Drug is recognized for treatment of the cancer indication by the NCCN Drugs and Biologics Compendium with Category of Evidence and Consensus of 1, 2A, or 2B
• OR
• Patient is less than 19 years of age

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Romvimza therapy

Approval duration

12 months